COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01086982
Recruitment Status : Suspended
First Posted : March 15, 2010
Last Update Posted : October 28, 2010
Information provided by:
Azidus Brasil

Brief Summary:
Check the pharmacodynamics of the drug octreotide acetate LAR 30 mg imported and distributed by Chemical Laboratory Pharmaceutical Bergamo Ltda. compared to the drug Sandostatin LAR ® (octreotide acetate 30 mg) manufactured by Novartis Biociências S / A, using as activity analysis of growth hormone (GH) and growth factor insulin-like 1 (IGF-1 ) after a single dose of the drug in patients with acromegaly

Condition or disease Intervention/treatment Phase
Acromegaly Drug: Octreotide acetate LAR Drug: Sandostatin LAR ® (octreotide acetate LAR) 30 MG Phase 1

Detailed Description:
Secondly, it will be observed safety (tolerability) in clinical patients by comparing the clinical and laboratory parameters before and after the study and the incidence of adverse events after a single dose

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : March 2010
Estimated Primary Completion Date : May 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Octreotide acetate LAR 30 MG
Drug: Octreotide acetate LAR
30 mg, single dose

Active Comparator: Sandostatin LAR ® (octreotide acetate LAR) 30 MG Drug: Sandostatin LAR ® (octreotide acetate LAR) 30 MG
30 mg, single dose

Primary Outcome Measures :
  1. Quantification of serum levels of GH and IGF-I. [ Time Frame: Before drug administration, after drug administration, 1, 3, 7, 14, 21, 28, 35, 42, 49, 56 and 63 days after. ]

Secondary Outcome Measures :
  1. Occurrence and severity of side effects during use of the product in order to ensure the security of it. [ Time Frame: After drug administration, 1, 3, 7, 14, 21, 28, 35, 42, 49, 56 and 63 days after. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Accept the Terms of Consent;

  • be aged over 18, regardless of sex;
  • Patients with acromegaly who presented GH levels ≥ 2.5 ng / mL or no suppression of GH levels to less than 1 ng / mL after tolerance test glucose and IGF-I levels for age and sex;
  • Patients undergoing hypophysectomy followed by radiotherapy or not and to keep níves increased GH and IGF-I;
  • Patients waiting hypophysectomy with increased levels of GH and IGF-I

Exclusion Criteria:

  • Have participated in any experimental study or have ingested any drug trial within six months prior to the start of the study;
  • Have made use of medications that influence the results, regular 4 weeks prior to the start of the study or having used any medication a week before the start of the study;
  • Have been treated with somastostatina analog or dopamine agonist in the last 2 months;
  • Present history of myocardial infarction, angina and / or heart failure;
  • Patients who present calculation of the gallbladder and have not undergone cholecystectomy;
  • Pregnant women and nursing;
  • Patients who have allergies to medicine;
  • Patients with a history of acute pancreatitis;
  • Patient with altered levels of amylase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01086982

Layout table for location information
LAL Clínica Pesquisa e Desenvolvimento Ltda
Valinhos, São Paulo, Brazil
Sponsors and Collaborators
Azidus Brasil
Layout table for additonal information
Responsible Party: Alexandre Frederico, LAL Clínica Pesquisa e Desenvolvimento Ltda Identifier: NCT01086982    
Other Study ID Numbers: OCTBER0409
Version 3
First Posted: March 15, 2010    Key Record Dates
Last Update Posted: October 28, 2010
Last Verified: March 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents